MEMORIAL DAY OFFER 50% OFF Premium Subscription Order Now MEMORIAL DAY 50% OFF Subscription >>

No Pain, No Gain.Week 21 On Stock Market Click to watch.

Amarin Corporation PLC Stock Forecast

NASDAQ:AMRN BUY SELL

$1.44 (0.70%)

Volume: 1.274M

Closed: May 27, 2022

Hollow Logo Score: -3.896

Amarin Corporation PLC Stock Forecast

BUY SELL NASDAQ:AMRN
$1.44 (0.70%)

Volume: 1.274M

Closed: May 27, 2022

Score Hollow Logo -3.896

Amarin Corporation PLC Stock Forecast NASDAQ:AMRN

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-24 4.17% Goldman Sachs $1.75 $1.50 Maintains Sell
2022-05-06 - JP Morgan - Downgrades Neutral Underweight
2022-05-05 108.33% SVB Leerink $10.00 $3.00 Downgrades Outperform Market Perform
2022-05-05 108.33% HC Wainwright & Co. $10.00 $3.00 Downgrades Buy Neutral
2022-02-16 594.44% SVB Leerink $11.00 $10.00 Maintains Outperform
2022-01-31 663.89% SVB Leerink $12.00 $11.00 Maintains Outperform
2021-09-09 733.33% SVB Leerink $12.00 Initiates Coverage On Outperform
2021-05-12 247.22% Goldman Sachs $6.00 $5.00 Downgrades Neutral Sell
2021-02-01 1011.11% SVB Leerink $12.00 $16.00 Maintains Outperform
2020-09-28 733.33% SVB Leerink $9.00 $12.00 Maintains Outperform
2020-08-26 1358.33% Piper Sandler $21.00 Initiates Coverage On Overweight
2020-05-04 663.89% Aegis Capital $9.00 $11.00 Maintains Buy
2020-05-04 525% SVB Leerink $7.00 $9.00 Maintains Outperform
2020-04-01 316.67% Citigroup $24.00 $6.00 Maintains Buy
2020-03-31 177.78% Jefferies $30.00 $4.00 Downgrades Buy Hold
2020-03-31 455.56% Stifel $24.00 $8.00 Maintains Hold
2020-03-31 - Oppenheimer - Upgrades Underperform Perform
2020-03-31 177.78% Goldman Sachs $27.00 $4.00 Downgrades Buy Neutral
2020-03-13 1844.44% Goldman Sachs $28.00 Upgrades Neutral Buy
2020-03-02 1497.22% Cowen & Co. $23.00 Initiates Coverage On Outperform
2020-02-26 733.33% Oppenheimer $13.00 $12.00 Maintains Underperform
2020-02-18 1566.67% Citigroup $27.00 $24.00 Upgrades Neutral Buy
2020-01-06 1427.78% JP Morgan $22.00 Initiates Coverage On Neutral
2019-12-16 455.56% Oppenheimer $7.00 $8.00 Maintains Underperform
2019-12-16 1705.56% Stifel $28.00 $26.00 Downgrades Buy Hold
2019-11-20 386.11% Oppenheimer $7.00 Initiates Coverage On Underperform
2019-11-18 1775% Citigroup $23.00 $27.00 Downgrades Buy Neutral
2019-10-31 1497.22% Aegis Capital $23.00 Initiates Coverage On Buy
2019-10-15 1080.56% Goldman Sachs $17.00 Initiates Coverage On Neutral

AMRN Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -46.77% during the next 3 months and, with a 90% probability hold a price between $0.38 and $1.31 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-06-01 $0.68 $1.55 $2.42
2022-06-02 $0.65 $1.52 $2.39
2022-06-03 $0.62 $1.48 $2.35
2022-06-06 $0.58 $1.45 $2.32
2022-06-07 $0.55 $1.42 $2.29
2022-06-08 $0.51 $1.38 $2.25
2022-06-09 $0.48 $1.35 $2.22
2022-06-10 $0.44 $1.31 $2.18
2022-06-13 $0.41 $1.28 $2.15
2022-06-14 $0.38 $1.25 $2.11
2022-06-15 $0.34 $1.21 $2.08
2022-06-16 $0.31 $1.18 $2.05
2022-06-17 $0.27 $1.14 $2.01
2022-06-21 $0.24 $1.11 $1.98
2022-06-22 $0.20 $1.07 $1.94
2022-06-23 $0.17 $1.04 $1.91
2022-06-24 $0.14 $1.01 $1.87
2022-06-27 $0.10 $0.97 $1.84
2022-06-28 $0.0679 $0.94 $1.81
2022-06-29 $0.0336 $0.90 $1.77
2022-06-30 $-0.0006 $0.87 $1.74
2022-07-01 $-0.0349 $0.83 $1.70
2022-07-05 $-0.0692 $0.80 $1.67
2022-07-06 $-0.10 $0.77 $1.63
2022-07-07 $-0.14 $0.73 $1.60
2022-07-08 $-0.17 $0.70 $1.57
2022-07-11 $-0.21 $0.66 $1.53
2022-07-12 $-0.24 $0.63 $1.50
2022-07-13 $-0.27 $0.59 $1.46
2022-07-14 $-0.31 $0.56 $1.43

About Amarin Corporation PLC

Amarin  PLC Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s lead product includes Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT